Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-market safety reassessment of Safflower and Aceglutamide Injection
ChiCTR2000031123Phase 4Not yet recruiting
- Sponsor
- The First Hospital of Jilin University
- Start
- Apr 2020
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Guhong Injection, sponsored by The First Hospital of Jilin University. Primary endpoints: Adverse events and Adverse drug reactions. Planned start Apr 2020; status: not yet recruiting.
02
Drugs
Guhong Injection
Beyond the preview
Go deeper on ChiCTR2000031123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000031123.